Diagnosis of localized prostate cancer: 10 years of progress

Current Opinion in Urology

Volumn 10, Issue 4, 2000, Pages 319-327

  Feneley, Mark R ^a   Partin, Alan W ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

BIOPSY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0033910048     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200007000-00006     Document Type: Review

References (199)

1. 1 Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1679-1684.
2. 2 Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995; 274:1445-1449.
3. 3 Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-294.
4. 4 Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 1997; 15:331-335.
5. 5 Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
6. 6 Boyle P, Maisonneuve P, Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 1995; 46:47-55.
7. 7 Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85:60-67.
8. 8 Stanford JL, Stephenson RA, Coyle LM, et al. Prostate cancer trends 1973-1995. SEER Program, NCI, NIH Pub. No. 99-4543. Bethesda, MD; 1999.
9. 9 Schroder FH, Kranse R, Rietbergen J, et al. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Eur Urol 1999; 35:539-543.
10. 10 Gohagan JK, Prorok PC, Kramer BS, et al. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial of the National Cancer Institute. Cancer 1995; 75 (Suppl.):1869-1873.
11. 11 Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91:1017-1024.
12. 12 Farkas A, Schneider D, Perrotti M, et al. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52:444-448.
13. 13 Meyer F, Moore L, Bairati I, Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999; 161:1189-1191.
14. 14 Smart CR. The results of prostate carcinoma screening in the US as reflected in the surveillance, epidemiology, and end results program. Cancer 1997; 80:1835-1844.
15. 15 Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999; 161:529-533.
16. 16 Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999; 162:293-306.
17. 17 McCormack RT, Rittenhouse HG, Finlay JA, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995; 45:729-744.
18. 18 Guinan P, Bush I, Ray V, et al. The accuracy of the rectal examination in the diagnosis of prostate carcinoma. N Engl J Med 1980; 303:499-503.
19. 19 Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269:57-60.
20. 20 Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270:948-954.
21. 21 Ellison LM, Heaney JA, Birkmeyer JD. Trends in the use of radical prostatectomy for treatment of prostate cancer. Eff Clin Pract 1999; 2:228-233.
22. 22 Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20:286-292.
23. 23 Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24:395-406.
24. 24 Ramos CG, Carvalhal GF, Smith DS, et al. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol 1999; 161:1525-1529.
25. 25 Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-114.
26. 26 Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445-1451.
27. 27 Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147:815-616.
28. 28 Catalona WJ, Richie JP, DeKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152:2031-2036.
29. 29 Presti JCJ, Hovey R, Bhargava V, et al. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations. J Urol 1997; 157:907-911.
30. 30 Horninger W, Reissigl A, Klocker H, et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate 1998; 37:133-137.
31. 31 Rietbergen JB, Kranse R, Hoedemaeker RF, et al. Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study. Urology 1998; 52:237-246.
32. 32 Djavan B, Zlotta AR, Byttebier G, et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998; 160:411-418.
33. 33 Keetch DW, McMurtry JM, Smith DS, et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 1996; 156:428-431.
34. 34 Carter HB, Pearson JD. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 1997; 24:333-338.
35. 35 Djavan B, Zlotta AR, Remzi M, et al. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology 1999; 54:846-852.
36. 36 Djavan B, Zlotta A, Kratzik C, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 1999; 54:517-522.
37. 37 Kalish LA, McKinlay JB. Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA. Urology 1999; 54:1022-1027.
38. 38 Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270:860-864.
39. 39 Dalkin BL, Ahmann FR, Kopp JB, et al. Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma. Br J Urol 1995; 76:346-350.
40. 40 Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53:581-589.
41. 41 Meshref AW, Bazinet M, Trudel C, et al. Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges. Urology 1995; 45:972-979.
42. 42 Bassler TJJ, Orozco R, Bassler IC, et al. Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant. Urology 1998; 52:1064-1069.
43. 43 Catalona WJ, Partin AW, Finlay JA, et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999; 54:220-224.
44. 44 Carter HB, Epstein JI, Partin AW. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53:126-130.
45. 45 Ukimura O, Durrani O, Babaian RJ. Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 1997; 50:66-72.
46. 46 Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 1997; 158:2162-2167.
47. 47 Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000; 163:158-162.
48. 48 Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909-916.
49. 49 Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141:1076-1083.
50. 50 Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143:747-752.
51. 51 Stamey TA, Dietrick DD, Issa MM. Large, organ confined, impalpable transition zone prostate cancer association with metastatic levels of prostate specific antigen. J Urol 1993; 149:510-515.
52. 52 Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154:407-413.
53. 53 Collins GN, Martin PJ, Wynn-Davies A, et al. The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice. J Urol 1997; 157:1744-1747.
54. 54 Ornstein DK, Rao GS, Smith DS, et al. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol 1997; 157:195-198.
55. 55 Lechevallier E, Eghazarian C, Ortega JC, et al. Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen. Urology 1999; 54:857-861.
56. 56 Lechevallier E, Echazarian C, Ortega JC, et al. Kinetics of postbiopsy levels of serum free prostate-specific antigen and percent free prostate-specific antigen. Urology 1999; 53:731-735.
57. 57 Oesterling JE, Roy J, Agha A, et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group. Urology 1998; 51:58-63.
58. 58 Stenner J, Holthaus K, Mackenzie SH, Crawford ED. The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology 1998; 51:455-459.
59. 59 Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 1997; 50:239-243.
60. 60 Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997; 24:283-291.
61. 61 Nixon RG, Wener MH, Smith KM, et al. Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997; 157:2183-2190.
62. 62 Ornstein DK, Smith DS, Rao GS, et al. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997; 157:2179-2182.
63. 63 Schwartz BF, Faught J, Jezior JR. The effect of colonoscopy on serum prostate specific antigen levels. BJU Int 1999; 84:302-304.
64. 64 Lujan M, Paez A, Sanchez E, et al. Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol 1999; 162:1311-1313.
65. 65 Carter HB, Pearson JD, Waclawiw Z, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45:591-596.
66. 66 Barry MJ, Girman CJ, O'Leary MP, et al. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group. J Urol 1995; 153:99-103.
67. 67 Bostwick DG, Qian J, Bergstralh E, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155:1361-1367.
68. 68 Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology 1993; 41:207-216.
69. 69 Murphy GP, Snow PB, Brandt J, et al. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint(R) scintiscans. Prostate 2000; 42:145-149.
70. 70 Potter SR, Miller MC, Mangold LA, et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999; 54:791-795.
71. 71 Mattfeldt T, Kestler HA, Hautmann R, Gottfried HW. Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibility study. BJU Int 1999; 84:316-323.
72. 72 Huber PR, Mattarelli G, Strittmatter B, et al. In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. Prostate 1995; 27:166-175.
73. 73 Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274:1214-1220.
74. 74 Arcangeli CG, Humphrey PA, Smith DS, et al. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 1998; 51:558-564.
75. 75 Pannek J, Rittenhouse HG, Chan DW, et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998; 159:1238-1242.
76. 76 Noldus J, Graefen M, Huland E, et al. The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. J Urol 1998; 159:2004-2007.
77. 77 Henricks WH, England BG, Giacherio DA, et al. Serum percent-free PSA does not predict extraprostatic spread of prostate cancer. Am J Clin Pathol 1998; 109:533-539.
78. 78 Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 1997; 157:544-547.
79. 79 Lerner SE, Jacobsen SJ, Lilja H, et al. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 1996; 48:240-248.
80. 80 Pannek J, Subong EN, Jones KA, et al. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology 1996; 48:51-54.
81. 81 Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 2000; 163:119-126.
82. 82 Southwick PC, Catalona WJ, Partin AW, et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 1999; 162:1346-1351.
83. 83 Nixon RG, Meyer GE, Blase AB, et al. Comparison of 3 investigational assays for the free form of prostate specific antigen. J Urol 1998; 160:420-425.
84. 84 Pannek J, Partin AW. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol 1998; 16:100-105.
85. 85 Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 1999; 45:1960-1966.
86. 86 Partin AW, Catalona WJ, Finlay JA, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999; 54:839-845.
87. 87 Djavan B, Bursa B, Seitz C, et al. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 1999; 54:603-606.
88. 88 Veltri RW, Miller MC, Zhao G, et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999; 53:139-147.
89. 89 Cooner WH, Mosley BR, Rutherford Jr CL, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143:1146-1152.
90. 90 Terris MK, McNeal JE, Freiha FS, Stamey TA. Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J Urol 1993; 149:1035-1039.
91. 91 Smith JAJ, Scardino PT, Resnick MI, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997; 157:902-906.
92. 92 Fornage BD, Touche DH, Deglaire M, et al. Real-time ultrasound-guided prostatic biopsy using a new transrectal linear-array probe. Radiology 1983; 146:547-548.
93. 93 Manyak MJ, Javitt MC. The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Semin Urol Oncol 1998; 16:145-152.
94. 94 Rifkin MD, Zerhouni EA, Gatsonis CA, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 1990; 323:621-626.
95. 95 Tempany CM, Zhou X, Zerhouni EA, et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group Project Comparison of three MR imaging techniques. Radiology 1994; 192:47-54.
96. 96 Spencer JA, Chng WJ, Hudson E, et al. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. Br J Radiol 1998; 71:1130-1135.
97. 97 Lee N, Newhouse JH, Olsson CA, et al. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999; 54:490-494.
98. 98 Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111 -capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999; 54:1058-1063.
99. 111-indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 1999; 85:1586-1592.
100. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998; 159:2041-2046.
101. 101 Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 1998; 37:261-269.
102. 102 Hanks GE, Krall JM, Pilepich MV, et al. Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: implications of RTOG data for patient management and trial design and stratification. Int J Radiat Oncol Biol Phys 1992; 23:293-298.
103. 103 Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597.
104. 104 Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142:71-75.
105. 105 Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45:2-12.
106. 106 Keetch DW, Catalona WJ. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol 1995; 154:1795-1797.
107. 107 Bazinet M, Karakiewicz PI, Aprikian AG, et al. Value of systematic transition zone biopsies in the early detection of prostate cancer. J Urol 1996; 155:605-606.
108. 108 Terris MK, Pham TQ, Issa MM, Kabalin JN. Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 1997; 157:204-206.
109. 109 Fleshner NE, Fair WR. Indications for transition zone biopsy in the detection of prostatic carcinoma. J Urol 1997; 157:556-558.
110. 110 Chang JJ, Shinohara K, Hovey RM, et al. Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. Urology 1998; 52:89-93.
111. 111 Mukamel E, DeKernion JB, Hannah J, et al. The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostate. Cancer 1987; 59:1535-1538.
112. 112 Stone NN, Stock RG, Parikh D, et al. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate. J Urol 1998; 160:1722-1726.
113. 113 Tefilli MV, Gheiler EL, Tiguert R, et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol 1998; 160:802-806.
114. 114 Daneshgari F, Taylor GD, Miller GJ, Crawford ED. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 1995; 45:604-609.
115. 115 Taneja SS, Penson DF, Epelbaum A, et al. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen. J Urol 1999; 162:1352-1357.
116. 116 Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999; 161:494-498.
117. 117 Karakiewicz PI, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. Urology 1997; 49:55-59.
118. 118 Uzzo RG, Wei JT, Waldbaum RS, et al. The influence of prostate size on cancer detection. Urology 1995; 46:831-836.
119. 119 Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol 1995; 153:1496-1498.
120. 120 Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997; 158:505-508.
121. 121 Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151:1571-1574.
122. 122 Norberg M, Egevad L, Holmberg L, et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50:562-566.
123. 123 Rabbani F, Stroumbakis N, Kava BR, et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159:1247-1250.
124. 124 Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997; 158:1886-1890.
125. 125 Stroumbakis N, Cookson MS, Reuter VE, Fair WR. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997; 49:113-118.
126. 126 Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998; 159:471-475.
127. 127 Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157:199-202.
128. 128 Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998; 160:2115-2120.
129. 129 Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 1996; 47:347-352.
130. 130 Chang JJ, Shinohara K, Bhargava V, Presti JCJ. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998; 160:2111-2114.
131. 131 Bauer JJ, Zeng J, Weir J, et al. Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer. Urology 1999; 53:961-967.
132. 132 Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163:152-157.
133. 133 Presti JCJ, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163:163-166.
134. 134 Eskew LA, Woodruff RD, Bare RL, McCullough DL. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J Urol 1998; 160:794-796.
135. 135 Chen ME, Troncoso P, Johnston DA, et al. Optimization of prostate biopsy strategy using computer based analysis. J Urol 1997; 158:2168-2175.
136. 136 Chen ME, Troncoso P, Tang K, et al. Comparison of prostate biopsy schemes by computer simulation. Urology 1999; 53:951-960.
137. 137 Feneley MR, Parkinson MC. Biopsy diagnosis of prostatic cancer-current areas of concern. J Clin Pathol 1997; 50:265-266.
138. 138 Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997; 21:566-576.
139. 139 Carlson GD, Calvanese CB, Kahane H, Epstein JI. Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. Urology 1998; 51:525-529.
140. 140 Wills ML, Sauvageot J, Partin AW, et al. Ability of sextant biopsies to predict radical prostatectomy stage. Urology 1998; 51:759-764.
141. 141 Ravery V, Szabo J, Toublanc M, et al. A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Br J Urol 1996; 77:724-728.
142. 142 Sebo TJ, Bock BJ, Cheville JC, et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 2000; 163:174-178.
143. 143 Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995; 153:1543-1548.
144. 144 Sanwick JM, Dalkin BL, Nagle RB. Accuracy of prostate needle biopsy in predicting extracapsular tumor extension at radical retropubic prostatectomy: application in selecting patients for nerve-sparing surgery. Urology 1998; 52:814-818.
145. 145 Graefen M, Hammerer P, Michl U, et al. Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy. Urology 1998; 51:437-442.
146. 146 Holmes GF, Walsh PC, Pound CR, Epstein JI. Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy. Urology 1999; 53:752-756.
147. 147 de la Taille A, Katz A, Bagiella E, et al. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999; 54:1039-1043.
148. 148 Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al. Systematic biopsies accurately predict extracapsutar extension of prostate cancer and persistent/ recurrent detectable PSA after radical prostatectomy. Urology 1994; 44:371-376.
149. 149 Presti JCJ, Shinohara K, Bacchetti P, et al. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology 1998; 52:1079-1084.
150. 150 Bostwick DG, Wheeler TM, Blute M, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996; 48:47-57.
151. 151 Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79:772-779.
152. 152 Badalament RA, Miller MC, Peller PA, et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996; 156:1375-1380.
153. 153 Veltri RW, O'Dowd GJ, Orozco R, Miller MC. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Semin Urol Oncol 1998; 16:106-117.
154. 154 Scherr DS, Vaughan EDJ, Wei J, et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy [published erratum appears in J Urol 1999; 162:503]. J Urol 1999; 162:12-16.
155. 155 Ruijter E, van de Kaa C, Aalders T, et al. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol 1998; 11:276-281.
156. 156 Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162:2040-2045.
157. 157 Zhang YH, Kanamaru H, Oyama N, et al. Comparison of nuclear morphometric results between needle biopsy and surgical specimens from patients with prostate cancer. Urology 1999; 54:763-766.
158. 158 Mackey TJ, Borkowski A, Amin P, et al. bcl-2/bax Ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998; 52:1085-1090.
159. 159 Mairinger T, Mikuz G, Gschwendtner A. Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. Prostate 1999; 41:12-19.
160. 160 Henneberry JM, Kahane H, Humphrey PA, et al. The significance of intraluminal crystalloids in benign prostatic glands on needle biopsy. Am J Surg Pathol 1997; 21:725-728.
161. 161 Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate 1990; 17:337-347.
162. 162 Woolf CM. An investigation of familial aspects of carcinoma of the prostate. Cancer 1960; 13:739-744.
163. 163 Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, et al. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995; 87:991-996.
164. 164 Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996; 77:138-143.
165. 165 Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150:797-802.
166. 166 Gronberg H, Isaacs SD, Smith JR, et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997; 278:1251-1255.
167. 167 Gronberg H, Xu J, Smith JR, et al. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1 [published erratum appears in Cancer Res 1998; 58:3191]. Cancer Res 1997; 57:4707-4709.
168. 168 Bova GS, Partin AW, Isaacs SD, et al. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 1998; 160:660-663.
169. 169 Walsh PC. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. J Urol 1998; 160:265-266.
170. 170 Cooney KA, McCarthy JD, Lange E, et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997; 89:955-959.
171. 171 Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274:1371-1374.
172. 172 Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998; 20:175-179.
173. 173 Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999; 64:776-787.
174. 174 Eeles RA, Durocher F, Edwards S, et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/ British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet 1998; 62:653-658.
175. 175 Berthon P, Valeri A, Cohen-Akenine A, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998; 62:1416-1424.
176. 176 Fleshner NE, Klotz LH. Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metast Rev 1998; 17:325-330.
177. 177 De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 1999; 53:29-39.
178. 178 Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9:553-557.
179. 179 Landstrom M, Zhang JX, Hallmans G, et al. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 1998; 36:151-161.
180. 180 Moyad MA. Soy, disease prevention, and prostate cancer. Semin Urol Oncol 1999; 17:97-102.
181. 181 Pollard M, Luckert PH. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats. Nutr Cancer 1997; 28:41-45.
182. 182 Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2:467-472.
183. 183 Ekman P. Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Eur Urol 1999; 35:362-369.
184. 184 Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90:440-446.
185. 185 Hartman TJ, Albanes D, Pietinen P, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 1998; 7:335-340.
186. 186 Denis L, Norton MS, Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol 1999; 35:377-387.
187. 187 Thompson IM, Coltman CAJ, Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate 1997; 33:217-221.
188. 188 Strategies for the chemoprevention of prostate cancer. Eur Urol 1999; 35:
189. 189 Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996; 29:117-134.
190. 190 Franks LM. The natural history of prostatic cancer. Lancet 1956; 2:1037-1039.
191. 191 Sakr WA. Prostatic intraepithelial neoplasia: a marker for high-risk groups and a potential target for chemoprevention. Eur Urol 1999; 35:474-478.
192. 192 Bostwick DG. High grade prostatic intraepithelial neoplasia: the most likely precursor of prostate cancer. Cancer 1995; 75:1823-1836.
193. 193 Qian J, Jenkins RB, Bostwick DG. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Eur Urol 1999; 35:479-483.
194. 194 Feneley MR, Busch C. Precursor lesions for prostate cancer and their clinical significance [Editorial]. J Royal Soc Med 1997; 90:533-539.
195. 195 Montironi R, Bostwick DG, Bonkoff H. Origins of prostate cancer. Cancer 1996; 78:362-365.
196. 196 Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996; 78:330-336.
197. 197 Epstein JI, Carmichael MJ, Partin AW, Walsh PC. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol 1994; 151:1587-1592.
198. 198 Feneley MR, Young MP, Chinyama C, et al. Ki-67 expression in early prostate cancer and associated pathological lesions. J Clin Pathol 1996; 49:741-748.
199. 199 De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155:1985-1992.